Mycosis fungoides and Sézary syndrome are primary cutaneous T cell malignancies derived from CD4 + skin-homing T cells 1, 2 . Mycosis fungoides cases with limited skin involvement have a favorable prognosis; however, the median survival time for cases with cutaneous tumors and generalized erythroderma is approximately 4 years, and patients with Sézary syndrome fare even worse, with survival times of about 2 years (refs. 2, 3) .
To investigate the genetic mechanisms of aggressive CTCLs, we performed whole-exome sequencing of 42 CTCL cases, including 25 Sézary syndrome cases and eight mycosis fungoides cases (Supplementary Table 1 ). For each sample, we generated an average of 115 million reads, resulting in an average coverage of 99.91% with over 95.3% of targeted regions showing >30× coverage (Supplementary Table 2 ).
In agreement with previous studies [4] [5] [6] [7] [8] , copy number analysis from exome data identified a median of 21 copy number alterations per sample (range of 0-56) in Sézary syndrome, with characteristic recurrent gains in chromosome 7 (5/25, 20%), 8q (13/25, 52%) and 17q (2/25, 8%), as well as recurrent deletions involving tumorsuppressor genes in 17p13.1 (TP53; 13/25, 52%), 13q14.2 (RB1; 4/25, 16%), 10q23.3 (PTEN, 5/25; 20%) and 12p13.1 (CDKN1B; 5/25, 20%) ( Fig. 1 and Supplementary Table 3) . Focal chromosome 2p23.3 deletions encompassing the DNMT3A locus were observed in five patients with Sézary syndrome (5/25, 20%), including two cases with focal homozygous deletion of this epigenetic tumor-suppressor gene. Notably, expression analysis of DNMT3A and TP53 showed reduced or complete absence of expression for these tumor suppressors in Sézary syndrome samples harboring 2p23.3 and 17p13.1 deletions, respectively ( Supplementary Fig. 1 ). In contrast, non-leukemic mycosis fungoides cases showed a lower number of copy number alterations per sample (median of 1, range of 0-2) (Supplementary Table 4) .
Mutation analysis showed a median of 39 nonsynonymous somatic mutations per sample (range of 1-182) in Sézary syndrome cases and 62 (range of 2-419) in mycosis fungoides cases (Supplementary Table 5 ). Overall, we identified 1,261 candidate high-confidence somatic mutations in Sézary syndrome affecting 1,123 different genes. Analysis of mutational processes 9 identified the presence of a mutational signature characterized by C>T substitutions at NpCpG trinucleotides, as well as a high frequency of C>A substitutions at CpCpN trinucleotides and C>T substitutions at CpCpN and TpCpN trinucleotides ( Supplementary  Fig. 2 ). Mutations in Sézary syndrome included loss-of-function lesions in TP53 (p.Arg213*, p.Arg342*, p.Pro177_Cys182del and p.Leu344Gln) and three mutations in TET2 (p.Gln1654*, p.Cys1932Phe and p.Gln649*), an epigenetic tumor-suppressor gene frequently mutated in myeloid malignancies and angioimmunoblastic T cell lymphoma 10 . Additional mutations in epigenetic regulator genes included loss-of-function mutations in the CREBBP histone acetyltransferase (p.Gln839* and p.Ser1207Profs*42), and the KMT2C (MLL3) histone H3 lysine 4 (H3K4) methyltransferase (p.Thr3941Hisfs*4), as well as mutations in components of the SWI/SNF (BRD9, p.Gln479His and p.His467_Leu468del; SMARCA4, p.Ser1238Tyr) and NuRD (CHD3, p.Gln660His and p.Ser230Leu) chromatin-remodeling complexes ( Fig. 2 and Supplementary Table 6 ). Analysis of mycosis fungoides identified 958 somatic mutations in 866 genes. These included a mutation in SMARCA4 (p.Arg251Lys) and two truncating mutations
The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome l e t t e r s in the KMT2D (MLL2) and MLL3 histone H3K4 methyltransferase genes (MLL2, p.Gln2418* and MLL3, p.Gly1246*) ( Fig. 2 and Supplementary Table 7 ). The functional relevance of mutations in epigenetic regulator genes in Sézary syndrome and CTCL is evidenced by the strongly deleterious alleles resulting in protein truncations identified in TET2 (p.Arg213* and p.Arg342*), CREBBP (p.Gln839* and p.Ser1207Profs*42) and MLL3 (p.Thr3941Hisfs*4 and p.Gly1246*). In addition, the TET2 mutation encoding p.Cys1932Phe maps to the critical C-terminal region of the DHSBH domain, which is recurrently disrupted by missense mutations in myeloid tumors and peripheral T cell lymphoma 11, 12 . The CHD3 mutation encoding p.Gln660His maps to the second chromodomain of this protein and is predicted to be strongly damaging (PolyPhen-2 score = 0.99), whereas the p.Ser230Leu substitution is located within the first PHD domain, which is implicated in the reading of repressive histone marks 13 . Similarly, both the SMARCA4 mutation encoding p.Ser1238Tyr and the BRD9 mutation encoding p.Gln479His have a high PolyPhen-2 score of 0.99, which is predictive of the variants being strongly damaging.
Signaling factor mutations included an activating mutation in the BRAF gene (p.Lys601Glu) 14 in a CD30 -CTCL sample and three mutations in MAPK1 involving the Glu322 codon (p.Glu322Ala and p.Glu322Lys) in two patients with mycosis fungoides. Notably, the MAPK1 mutation encoding p.Glu322Lys has been reported as an activating allele 15 , and expression of both Glu322Lys and Glu322Ala MAPK1 (ERK2) resulted in increased ERK1 and ERK2 (ERK1/2) activation (Supplementary Fig. 3) . We also found a JAK3 mutation previously reported in prolymphocytic leukemia (p.Val678Leu) 16 cooccurring with a loss-of-function mutation in SH2B3 (p.Tyr273*), a negative regulator of JAK signaling, and an activating mutation in STAT3 (p.Tyr640Phe) 17 in two mycosis fungoides cases. In addition, we identified two mutations in PREX2, which encodes a phosphatidylinositol 3,4,5-trisphosphate RAC exchange factor involved in regulation of the PTEN tumor suppressor 18 (Fig. 2) . Notably, the PREX2 mutation encoding p.Arg297Cys present in a mycosis fungoides sample is recurrently found in melanoma 19 , and the PREX2 variant encoding p.Glu1295Lys found in a CD30 -CTCL case has been reported in melanoma, cutaneous squamous cell carcinoma, and head and neck cancer 19 . Finally, we identified three point mutations in Sézary syndrome in PLCG1, an oncogene described as carrying gain-of function mutations in CTCL 8, 20 . One of the variants (p.Gly722Val) is new, whereas the other two (p.Arg48Trp and p.Glu1163Lys) have been previously reported 8 .
The nuclear factor (NF)-κB pathway is known to be recurrently activated in CTCL and Sézary syndrome 21 . Alterations in TNFR2 (tumor necrosis factor receptor 2) leading to NF-κB activation have recently been identified in mycosis fungoides and Sézary syndrome 7 . In agreement with previous results, we identified two mutations in TNFRSF1B (encoding TNFR2) in our Sézary syndrome cohort (p.Gly256Cys and p.Thr377Ile) 7 . However, these analyses also identified the presence of two mutations located close to each other in CARD11 (p.Ser615Phe and p.Glu626Lys), another important mediator of NF-κB activation, in two Sézary syndrome cases. Both CARD11 mutations identified in our analysis map to the so-called linker domain of the protein (Fig. 3a) . This is in contrast with diffuse large B cell lymphoma (DLBCL), where Signaling   SS_L1  SS_L2  SS_L3  SS_L4  SS_L5  SS_L6  SS_L7  SS_L8  SS_L9  SS_L10  SS_L11  SS_L12  SS_L13  SS_L14  SS_L15  SS_L16  SS_L17  SS_L18  SS_L19  SS_L20  SS_L21  SS_L22  SS_L23  SS_NU8  CTCL_NU6  SS_NU15  CTCL_NU2  CTCL_NU4  CTCL_NU7  CTCL_NU9  CTCL_NU11  CTCL_NU18  CTCL_NU19  CTCL_NU1  CTCL_NU3  CTCL_NU12  CTCL_NU13  CTCL_NU14  CTCL_NU16  CTCL_NU17  CTCL_NU20 npg l e t t e r s CARD11 mutations typically map to the coiled-coil domain 22 . Under basal conditions, CARD11 adopts an inactive, closed configuration, which upon T cell receptor (TCR) activation and consequent protein Figure 2 Somatic alterations in Sézary syndrome and CTCL. Schematics of TP53, the epigenetic factors TET2, BRD9, MLL3, MLL2, CREBBP, SMARCA4 and CHD3, and the CARD11, BRAF, MAPK1, PREX2, cGKIβ, JAK3, SH2B3 and STAT3 signaling proteins show somatic alterations identified in this study. Black circles represent amino acid substitutions; the blue circle represents an amino acid substitution different from the one indicated by the black circle at the same position; red circles represent truncating mutations. Cys, cysteine-rich domain; DHSBH, double-stranded β-helix fold domain; Bromo, bromodomain; PHD, plant homeodomain; HMG, high-mobility-group domain; FYRN 'FY-rich' domain, N terminal; FYRC, 'FY-rich' domain, C terminal; SET, Su(var), enhancer of zeste and trithorax; Z, zinc-finger domain; KIX, binding site of CREB; HAT, histone acetyltransferase domain; Q, glutamine-rich domain; QLQ, Gln-Leu-Gln motif; HSA, helicase/SANT-associated domain; BRK, Brahma and Kismet domain; Snf2_N, Snf2 family N-terminal domain; HELIC, helicase superfamily C-terminal domain; SnAC, Snf2-ATP-coupling, chromatin-remodeling complex; Chromo, chromatin organization modifier; CC, coiled-coil domain; SIM, SUMO-interacting domain; CARD, caspase recruitment domain; PDZ, PSD-95 (95-kDa protein involved in signaling in the postsynaptic density), Drosophila disc large tumor suppressor (Dlg1), Zonula occludens-1 protein (zo-1); SH3, Src homology 3 domain; GUK, guanylate kinase domain; TAD, transactivation domain; P rich, proline-rich domain; TD, tetradimerization domain; NR, negative regulation domain; RBD, Rasbinding domain; C1, PKC conserved region 1 domain; DH, DBL homology domain; PH, pleckstrin homology domain; DEP domain, Dishevelled, Egl-10 and Pleckstrin domain; DIM/LZ, dimerization and leucine-zipper domain; IS, autoinhibitory domain; cGMP, cyclic GMP-binding domain; ATP, ATP-binding domain; SB, substrate-binding domain; FERM, 4.1protein/ezrin/radixin/moesin domain; SH2, Src homology 2 domain; Phe-ZIP, phenylalanine zipper. npg l e t t e r s downstream NF-κB signaling 23 . To test the functional relevance of the mutations identified, we first analyzed the effects of expressing wild-type, Ser615Phe and Glu626Lys CARD11 in NF-κB luciferase reporter assays in transfected HEK293T cells (Fig. 3b) . Expression of both Ser615Phe and Glu626Lys CARD11 resulted in increased NF-κB luciferase reporter activity in comparison to expression of wild-type CARD11. Moreover, lentiviral transduction with constructs for Ser615Phe and Glu626Lys CARD11 in Jurkat T cells expressing npg l e t t e r s GFP under the control of an NF-κB promoter resulted in increased NF-κB-driven GFP levels in comparison to control transduction with construct for wild-type CARD11 (Fig. 3c,d) . Treatment of Jurkat cells expressing Ser615Phe and Glu626Lys CARD11 with phorbol 12-myristate 13-acetate (PMA) plus ionomycin to mimic TCR activation resulted in further increased NF-κB-driven GFP expression (Fig. 3e) . Finally, Jurkat cells expressing Ser615Phe and Glu626Lys CARD11 showed earlier, increased and more sustained JNK phosphorylation after treatment with PMA plus ionomycin in comparison with control cells expressing wild-type CARD11 (Fig. 3f) , a result consistent with increased CARD11 activation downstream of TCR signaling. Next, we compared the activity of the CARD11 linker domain mutants to that of well-characterized CARD11 mutants from DLBCL with alterations in the coiled-coil domain that show weak (Met183Leu), strong (Asp230Asn) and very strong (Leu251Pro) effects on NF-κB activation 22 . In the absence of stimulation with PMA plus ionomycin, CARD11 linker domain mutants showed moderate NF-κB luciferase reporter activity, intermediate between that of the Met183Leu and Asp230Asn CARD11 coiled-coil domain mutants ( Supplementary  Fig. 4 ). However, in cells treated with PMA plus ionomycin, CARD11 linker domain mutants showed stronger NF-κB activation, similar to that observed with expression of the Asp230Asn and Leu251Pro CARD11 coiled-coil domain mutants that have strong effects on NF-κB activation ( Fig. 3e and Supplementary Fig. 4) . Finally, we also identified two mutations altering the cGKIβ protein (p.Glu17Lys and p.Arg21Gln), one of the two cyclic GMP-dependent protein kinases (cGKIα and cGKIβ) generated by alternative splicing of the PRKG1 gene 24 , in two Sézary syndrome samples (Fig. 4a) . In T cells, cGKIβ antagonizes TCR activation-induced interleukin (IL)-2 release and cell proliferation 25, 26 . Structurally, the two PRKG1 mutations in our series map to the N-terminal dimerization and leucine-zipper domain of cGKIβ (ref. 27) (Fig. 4a) , which mediates the formation of homodimers implicated in activation of cyclic GMPregulated protein kinase (cGK) 25, 28 . Urea dissociation experiments with immunoprecipitated cGKIβ complexes showed reduced stability of wild type-Glu17Lys and wild type-Arg21Gln cGKIβ dimers in comparison with wild-type cGKIβ homodimer control (Fig. 4b,c) . Moreover, Jurkat cells expressing Glu17Lys and Arg21Gln cGKIβ showed decreased cGKIβ-mediated ERK1/2 activation 29 after stimulation with the cGMP analog 8-(4-Chlorophenylthio)-guanosine 3′,5′-cyclic monophosphate (8-CPT-cGMP), in comparison with control cells expressing wild-type cGKIβ (Fig. 4d) . Additionally, Jurkat cells expressing Glu17Lys and Arg21Gln cGKIβ treated with 8-CPT-cGMP also failed to phosphorylate RHOA at Ser188 (Fig. 4d) 30 . These results support the hypothesis that the N-terminal cGKIβ alterations identified in Sézary syndrome samples are loss-of-function variants resulting in reduced signal transduction ability. Consistent with this hypothesis, Jurkat cells expressing Glu17Lys and Arg21Gln cGKIβ showed increased NFAT activity after PMA plus ionomycin stimulation in comparison with control cells expressing wild-type cGKIβ, supporting a positive role for cGKIβ alterations in enhancing the TCR signaling response (Fig. 4e) . These results are in agreement with data describing mutations in genes activating NF-κB and NFAT signaling in CTCL 20 .
Immunoblot analysis of signaling pathway components showed high levels of phosphorylated STAT3, phosphorylated ERK, phosphorylated JNK and nuclear p50 NF-κB1 in most CTCL lines ( Supplementary  Fig. 5) . Therapeutically, inhibition of JAK signaling with tofacitinib and ruxolitinib was highly effective in HUT78 cells harboring a JAK3 mutation encoding p.Ala573Val. Inhibition of NF-κB signaling with MI-2 and bortezomib was broadly and highly effective across all four cell lines tested (HH, HUT78, HUT102 and SeAX). In contrast, MEK1/2 inhibition with U0126 and inhibition of NFAT with FK506 showed only modest antitumor effects (Supplementary Fig. 6 ).
Our results identify new genetic drivers in the pathogenesis of Sézary syndrome and point to TCR-controlled signaling pathways as potential targets in treating this disease. Extended analysis of clinically annotated series and further genetic characterization, including whole-genome sequencing and transcriptomic analysis, will be instrumental to elucidate the complete repertoire of genetic driver alterations in Sézary syndrome and CTCL.
MeTHoDS
Methods and any associated references are available in the online version of the paper. Table 2 ). We mapped reads to the hg19 reference genome using the Burrows-Wheeler Aligner (BWA) alignment tool, version 0.5.9. Mean depth (defined as the mean number of reads covering the captured coding sequence of a haploid reference) was 143.51×, with 95.3% of the genome covered by more than 30×. We identified sites that differed from the reference genome (called variants here) in each sample independently. The average number of germline SNPs was 19,631, comparable with previous reports 12 . Most of the candidate germline SNPs (~90% of germline variants) were reported in the dbSNP database. We used the SAVI algorithm (Statistical Algorithm for Variant Identification) 31 developed at Columbia University and constructed empirical priors for the distribution of variant frequencies in each sample. Following SAVI's Bayesian framework, we obtained a corresponding high-credibility interval for the frequency of each variant (posterior probability ≥1 × 10 −5 ) and tested the null hypothesis that variants were due to sequencing errors. We found that, for variants observed with a frequency of 0-2%, it was not possible to reject the null hypothesis and distinguish true mutations from sequencing errors. Consequently, we considered variants observed with a frequency of 0-2% to be absent. Also using the SAVI algorithm, we obtained high-credibility intervals for the corresponding change in frequency between tumor and normal samples (posterior probability ≥1 × 10 −5 ). Consistent with Sanger sequencing sensitivity and on the basis of our previously published specificity assessment (showing a false positive rate of 2.9% for variants called in >20% of reads and 18.3% for variants called in 3-20% of reads) 32 , we retained candidate somatic variants in CTCL samples that were absent from the normal sample and present in the tumor sample in ≥15% of the reads with at least 1% change in frequency relative to the normal sample with high posterior probability (≥1 × 10 −5 ). We excluded variants in regions with low coverage depth (<10×) or in regions with extremely high coverage depth (>300×), associated with genomic repetitive elements. We also removed all variants that were found to be present in any of this study's normal subjects or in any one of 220 exomes from unaffected individuals that were analyzed at our institution. Additionally, for Sézary syndrome samples for which control DNA was obtained from blood after the depletion of CD4 + cells (SS_L1-23), we retained as candidate somatic variants ones that were present in control DNA at frequencies <20% if the variant allele frequency (VAF) increased by >2-fold in tumor DNA, to account for contaminating tumor lymphocytes in the control preparation.
For analysis of mutational processes, we used the Wellcome Trust Sanger Institute's framework 9 implemented in MATLAB scripts. To identify mutational signatures in Sézary syndrome, we used all synonymous and nonsynonymous variants. We assessed signature stability and computed average Frobenius reconstruction error for k = 1 to 10 signatures. Significant reduction in reconstruction error up to k = 3, as well as stable reproducibility between k = 1 and k = 3, indicated three signatures recognized by the algorithm.
Identification of recurrent and focal copy number variants. Somatic CNVs were identified from the depth of coverage using EXCAVATOR 33 with default parameters. Tumor samples for which the matching normal sample was collected from buccal swabs were analyzed with EXCAVATOR pooled mode, which compares tumor depth of coverage with a compendium of the coverage depth for all normal samples. The normal compendium for the X and Y chromosomes was computed according to patient sex, to avoid diploid biases. Tumor samples for which the matching normal sample was collected from granulocytes were analyzed with EXCAVATOR somatic mode, which performs a pairwise tumor-normal comparison for each case. For these cases, we obtained additional statistical significance for CNVs with the following approach: for all sequenced exons, we computed the ratio of the depth of coverage in the tumor sample to the total depth of coverage in both the tumor and normal samples. These ratios, by definition, have values between 0 and 1, which we assumed follow a beta distribution. Following the Bayesian workflow described in the SAVI algorithm, we constructed an empirical prior for the ratios taken from all exons and calculated a posterior distribution for the value of each ratio. The P values for comparison to the null hypothesis that an exon has no copy number alterations were thus computed. Finally, we obtained the statistical significance for each CNV by taking the geometric mean of the P values of the exons within the altered region. We included the CNVs with confidence of at least 95% in the final list.
Quantitative RT-PCR. We performed reverse transcription reactions with the ThermoScript RT-PCR system (Invitrogen) and analyzed the resulting cDNA products by quantitative RT-PCR (FastStart Universal SYBR Green Master Mix, Roche) using a 7300 Real-Time PCR system (Applied Biosystems). geNorm pairwise variation (V) analysis was performed to determine the optimal number of reference genes for data normalization. Primer sequences are listed in Supplementary Table 8. 
